Survival outcomes and epidemiology of Merkel cell carcinoma of the lower limb and hip: A Surveillance, Epidemiology, and End Results analysis 2000-2018.
MCC, Merkel cell carcinoma
MCPyV, Merkel cell polyomavirus
Merkel
OS, overall survival
SEER
SEER, Surveillance, Epidemiology, and End Results
SOC, standard of care
carcinoma
population
survival
treatment
Journal
JAAD international
ISSN: 2666-3287
Titre abrégé: JAAD Int
Pays: United States
ID NLM: 101774762
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
accepted:
20
12
2021
entrez:
4
3
2022
pubmed:
5
3
2022
medline:
5
3
2022
Statut:
epublish
Résumé
Merkel cell carcinoma of lower limb and hip skin is a rare skin tumor that has a high recurrence rate. To assess epidemiology and survival outcomes of the lower limb and hip Merkel cell carcinoma, which are less addressed in the literature. The Surveillance, Epidemiology, and End Results database was searched for all cases of skin Merkel cell carcinoma between 2000 and 2018. Demographic and clinicopathologic features were compared between lower limb and other skin localizations using the In total, 976 patients were identified. The mean age was 72.7 years. The median OS was 68 months, better than that of other localizations. Older age, regional lymph node, and distant metastasis were associated with low OS. Surgery with >1-cm margins, when associated with radiotherapy, had the best OS. Age, tumor size, lymph node status, presence of metastasis, and treatment sequence were identified as independent prognostic factors. Lower limb and hip Merkel cell carcinomas have better OS than tumors in other skin localizations. In this dataset, the best OS was ensured using surgery with >1-cm margins and adjuvant radiotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Merkel cell carcinoma of lower limb and hip skin is a rare skin tumor that has a high recurrence rate.
OBJECTIVE
OBJECTIVE
To assess epidemiology and survival outcomes of the lower limb and hip Merkel cell carcinoma, which are less addressed in the literature.
METHODS
METHODS
The Surveillance, Epidemiology, and End Results database was searched for all cases of skin Merkel cell carcinoma between 2000 and 2018. Demographic and clinicopathologic features were compared between lower limb and other skin localizations using the
RESULTS
RESULTS
In total, 976 patients were identified. The mean age was 72.7 years. The median OS was 68 months, better than that of other localizations. Older age, regional lymph node, and distant metastasis were associated with low OS. Surgery with >1-cm margins, when associated with radiotherapy, had the best OS. Age, tumor size, lymph node status, presence of metastasis, and treatment sequence were identified as independent prognostic factors.
CONCLUSION
CONCLUSIONS
Lower limb and hip Merkel cell carcinomas have better OS than tumors in other skin localizations. In this dataset, the best OS was ensured using surgery with >1-cm margins and adjuvant radiotherapy.
Identifiants
pubmed: 35243404
doi: 10.1016/j.jdin.2021.12.010
pii: S2666-3287(21)00112-7
pmc: PMC8873923
doi:
Types de publication
Journal Article
Langues
eng
Pagination
13-21Informations de copyright
© 2021 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
None disclosed.
Références
JAMA Dermatol. 2019 Jul 1;155(7):803-811
pubmed: 30825411
J Am Acad Dermatol. 2003 Nov;49(5):832-41
pubmed: 14576661
J Plast Reconstr Aesthet Surg. 2014 Mar;67(3):e71-7
pubmed: 24125874
Lancet Oncol. 2016 Oct;17(10):1374-1385
pubmed: 27592805
Dermatol Clin. 2019 Jul;37(3):269-277
pubmed: 31084721
Front Oncol. 2013 Nov 14;3:276
pubmed: 24294591
Ann Surg Oncol. 2012 Oct;19(11):3325-34
pubmed: 22820936
Br J Dermatol. 2015 Jul;173(1):42-9
pubmed: 25919492
J Am Acad Dermatol. 2010 Nov;63(5):751-61
pubmed: 20646783
Clin Cancer Res. 2021 May 1;27(9):2494-2504
pubmed: 33547200
Future Oncol. 2017 Aug;13(19):1699-1710
pubmed: 28605939
J Natl Compr Canc Netw. 2018 Jun;16(6):742-774
pubmed: 29891526
Eur J Cancer. 2018 May;94:47-60
pubmed: 29533867
J Comp Eff Res. 2018 Sep;7(9):881-890
pubmed: 30107762
Ann Surg Oncol. 2021 Jan;28(1):519-529
pubmed: 32405979
J Am Acad Dermatol. 2019 Apr;80(4):1154-1156
pubmed: 30876535
J Am Acad Dermatol. 2017 Jul;77(1):142-148.e1
pubmed: 28495499
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):393-7
pubmed: 19515508
J Am Acad Dermatol. 2013 Mar;68(3):425-32
pubmed: 23200197
J Natl Compr Canc Netw. 2016 Oct;14(10):1247-1257
pubmed: 27697979
Radiother Oncol. 2019 May;134:211-219
pubmed: 31005218
Curr Probl Cancer. 2012 Jul-Aug;36(4):216-24
pubmed: 22481009
J Am Acad Dermatol. 2018 Mar;78(3):457-463.e2
pubmed: 29102486
J Dermatol. 2021 Jul;48(7):1027-1034
pubmed: 33847013
Oncoscience. 2017 Sep 14;4(7-8):106-114
pubmed: 28966943
Cancer Res. 2015 Dec 15;75(24):5228-34
pubmed: 26627015
Australas J Dermatol. 2020 Feb;61(1):e34-e38
pubmed: 32040877
Eur J Cancer. 2015 Nov;51(16):2396-403
pubmed: 26257075
J Natl Cancer Inst. 2010 Jun 2;102(11):793-801
pubmed: 20424236
J Natl Cancer Inst. 2009 Jul 1;101(13):938-45
pubmed: 19535775
J Am Acad Dermatol. 2008 Mar;58(3):375-81
pubmed: 18280333
Laryngoscope. 2012 Jun;122(6):1283-90
pubmed: 22522673
Dermatol Online J. 2018 Feb 15;25(2):
pubmed: 30865403
Dermatol Pract Concept. 2018 Apr 30;8(2):149-157
pubmed: 29785334
J Cutan Pathol. 2010 Jan;37(1):20-7
pubmed: 19638070